Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948495 | 0.82 | — | — | |
| SCHEMBL23948493 | 0.71 | SLC6A5 (0.46) | DNM1CA1CA2LMNAMEN1 | |
| SCHEMBL23948875 | 0.70 | — | — | |
| SCHEMBL27635701 | 0.67 | — | — | |
| SCHEMBL27443292 | 0.65 | — | — | |
| SCHEMBL27485200 | 0.65 | — | — | |
| Fluoride SCHEMBL27619226 | 0.61 | — | — | |
| Fluoride Ion SCHEMBL27619225 | 0.61 | — | — | |
| SCHEMBL23948566 | 0.60 | ALDH1A1 (0.38) | NFKB1TSHRLMNAMEN1KMT2A | |
| SCHEMBL23839266 | 0.59 | GRIN2D (0.37) | NFKB1DNM1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419963-B2 | Diels-Alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-115968304-A | Diels-Alder conjugation methods | 瑞泽恩制药公司 | 2023-04-14 | — | — | CN | disclosed |
| EP-4135775-A1 | DIELS-ALDER CONJUGATION METHODS | Regeneron Pharmaceuticals, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220378918-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS INC. (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2021211984-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211984-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | NFKB1 3908/4885DNM1 1253/4885CA12 1051/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | NFKB1 3908/4885DNM1 1253/4885CA12 1051/4885 |
| US-20220378918-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | NFKB1 3908/4885DNM1 1253/4885CA12 1051/4885 |
| US-12419963-B2 | Diels-Alder conjugation methods | GLUL, TGM2, GLS | NFKB1 3908/4885DNM1 1253/4885CA12 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.